CDER reorganization
This article was originally published in The Tan Sheet
Executive Summary
Office of Postmarketing Drug Risk Assessment and Office of Biostatistics would be transferred out of Office of Review Management and report directly to CDER Deputy Director Steven Galson, MD, under proposal floated by CDER Director Janet Woodcock, MD, in May 15 memo to staff. ORM would still report to Woodcock and contain ODEs I-V, but would be renamed Office of New Drugs to "more accurately and simply reflect its primary function." ORM has grown from overseeing two drug evaluation offices in 1994 to its current five drug offices, OPDRA and OB
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning